HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

Cristina Belizna, Francesca Pregnolato, Sebastien Abad, Jaume Alijotas-Reig, Howard Amital, Zahir Amoura, Laura Andreoli, Emmanuel Andres, Achile Aouba, Sule Apras Bilgen, Laurent Arnaud, Boris Bienvenu, Viktoria Bitsadze, Patrick Blanco, Miri Blank, Maria Orietta Borghi, Antonia Caligaro, Elisabeta Candrea, Valentina Canti, Laurent ChicheJean Marie Chretien, Jan Willem Cohen Tervaert, Laura Damian, Teresa Delross, Emmanuelle Dernis, Katrien Devreese, Aleksandra Djokovic, Enrique Esteve-Valverde, Maria Favaro, Céline Fassot, Raquel Ferrer-Oliveras, Alban Godon, Mohamed Hamidou, Milena Hasan, Daniel Henrion, Bernard Imbert, Pierre Yves Jeandel, Pascale Jeannin, Patrick Jego, Noemie Jourde-Chiche, Jamilya Khizroeva, Olivier Lambotte, Cédric Landron, Jose Omar Latino, Estibaliz Lazaro, Karina de Leeuw, Thomas Le Gallou, Levent Kiliç, Maarten Limper, Laurent Loufrani, Romain Lubin, Nadine Magy-Bertrand, Guillaume Mahe, Alexander Makatsariya, Thierry Martin, Christian Muchardt, Gyorgy Nagy, Loukman Omarjee, Pieter Van Paasen, Gilles Pernod, Florence Perrinet, Gilberto Pïres Rosa, Marc Antoine Pistorius, Amelia Ruffatti, Fatma Said, Patrick Saulnier, Damien Sene, Loic Sentilhes, Ova Shovman, Jean Sibilia, Crina Sinescu, Natasa Stanisavljevic, Ljudmila Stojanovich, Lai Shan Tam, Angela Tincani, Fréderic Tollis, Sebastian Udry, Marie Noelle Ungeheuer, Mathilde Versini, Ricard Cervera, Pier Luigi Meroni

Research output: Contribution to journalReview articleResearchpeer-review

24 Citations (Scopus)

Abstract

© 2018 The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%–21% at 5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4–16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.
Original languageEnglish
Pages (from-to)1153-1168
JournalAutoimmunity Reviews
Volume17
Issue number12
DOIs
Publication statusPublished - 1 Dec 2018

Keywords

  • Antiphospholipid syndrome
  • Hydroxychloroquine
  • Primary antiphospholipid syndrome
  • Secondary prevention

Fingerprint Dive into the research topics of 'HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome'. Together they form a unique fingerprint.

Cite this